Recent Updates — BHC

Bausch Health Companies Inc. reported third-quarter consolidated revenues of $2.94 billion, a 10% increase from the prior year period. GAAP net income attributable to Bausch Health was $436 million, or $1.15 per diluted share, compared to $0.48 in the previous year. Adjusted earnings per diluted share rose 53% to $1.77, and consolidated adjusted EBITDA increased 32% to $1,305 million. The company raised its full-year 2026 revenue guidance to a range of $10.975 billion to $11.175 billion and adjusted EBITDA guidance to $4.315 billion to $4.415 billion. Additionally, the board authorized a $50 million share repurchase program intended to offset anticipated management equity vesting dilution in 2027. Bausch Health is a global diversified pharmaceutical company developing and marketing products in gastroenterology, hepatology, neuroscience, dermatology, and eye health.

Bausch Health Companies Inc. reported second quarter 2026 results with consolidated revenues of $2.85 billion, a 13% increase from the prior year period. GAAP net income attributable to Bausch Health was $258 million, or $0.68 per diluted share, compared to $148 million and $0.40 per share in the previous year. Adjusted EBITDA reached $1,075 million, up 28% from the prior year. The company raised its full-year 2026 guidance for revenue to between $10.79 billion and $11.04 billion and adjusted EBITDA to between $4.05 billion and $4.175 billion. Bausch Health operates as a global diversified pharmaceutical and eye health company.

Michael Goettler resigned from the Board of Directors of Bausch Health Companies Inc., effective June 30, 2026, to become President and CEO of Knoa Pharma LLC. The resignation was not due to any disagreement with the Company's operations, policies, or practices. Bausch Health Companies Inc. is a global eye care and pharmaceutical company.